TY - JOUR
T1 - The potential for clinical translation of antibody-targeted nanoparticles in the treatment of acute myeloid leukaemia
AU - Guo, Jianfeng
AU - Luan, Xue
AU - Cong, Zhongcheng
AU - Sun, Yao
AU - Wang, Limei
AU - McKenna, Sharon L.
AU - Cahill, Mary R.
AU - O'Driscoll, Caitriona M.
N1 - Publisher Copyright:
© 2018 Elsevier B.V.
PY - 2018/9/28
Y1 - 2018/9/28
N2 - Acute myeloid leukaemia (AML) is a heterogeneous haematopoietic malignancy. Currently, treatment options offer a 5 year survival of <60%. In elderly patients, where the incidence is highest, the survival is much lower. Current standard treatments have significant toxicity and are least well tolerated in older adults, where the need is greatest. Therefore, alternatives are required. Monoclonal antibodies (mAbs), due to the specific targeting to cell surface proteins (i.e. antigens), represent a promising strategy for drug delivery to malignant cells. This concept favours the therapeutic ratio simultaneously by reducing toxicity and increasing efficacy. Although delivery of chemotherapeutics, genes and imaging agents using multifunctional nanoparticles has been substantially explored in treating solid cancers, less information on this approach is available in the case of AML. This review describes the development of antibody-targeted nanoparticulate drug delivery systems, and discusses the barriers to clinical translation in the treatment of AML.
AB - Acute myeloid leukaemia (AML) is a heterogeneous haematopoietic malignancy. Currently, treatment options offer a 5 year survival of <60%. In elderly patients, where the incidence is highest, the survival is much lower. Current standard treatments have significant toxicity and are least well tolerated in older adults, where the need is greatest. Therefore, alternatives are required. Monoclonal antibodies (mAbs), due to the specific targeting to cell surface proteins (i.e. antigens), represent a promising strategy for drug delivery to malignant cells. This concept favours the therapeutic ratio simultaneously by reducing toxicity and increasing efficacy. Although delivery of chemotherapeutics, genes and imaging agents using multifunctional nanoparticles has been substantially explored in treating solid cancers, less information on this approach is available in the case of AML. This review describes the development of antibody-targeted nanoparticulate drug delivery systems, and discusses the barriers to clinical translation in the treatment of AML.
KW - Bone marrow microenvironment
KW - Leukaemia-associated antigens
KW - Non-viral delivery vectors
KW - Translational research
UR - https://www.scopus.com/pages/publications/85050525409
U2 - 10.1016/j.jconrel.2018.07.024
DO - 10.1016/j.jconrel.2018.07.024
M3 - Review article
C2 - 30016734
AN - SCOPUS:85050525409
SN - 0168-3659
VL - 286
SP - 154
EP - 166
JO - Journal of Controlled Release
JF - Journal of Controlled Release
ER -
